The speaker has a very bearish outlook, stating that the company 'cannot recover.'

The speaker is bullish on this biotech stock, noting that a rumored deal has finally been announced.

The speaker had a successful, high-risk, event-driven long position that he has now completely sold. There is no longer an active investment thesis.

The host is extremely bearish due to the Phase 3 study failing its primary endpoint, refers to it as a 'scam company', holds a short position, and suggests the stock should be trading at $0.50.

A speaker expressed extreme skepticism, alleging signs of data manipulation in prior trials and calling the data 'fugazi,' suggesting the upcoming Phase 3 results are highly risky and a potential short opportunity.

The speaker is 'all in' on a short position, expecting the stock to fall to ~$0.80 from its current ~$5.54 price upon the release of what they are highly confident will be negative Phase 3 trial data.

The speaker believes the company's upcoming Phase 3 clinical trial has a 0% probability of success due to a lack of scientific mechanism, an irrelevant drug target, and weak prior clinical data, making it a clear short opportunity.

The speaker has an extremely bearish, high-conviction short thesis, believing the stock is headed towards zero due to an upcoming clinical data release expected to be poor around mid-September.

The speaker has an extremely bearish view and a high-conviction short idea, predicting the stock will go to zero soon.

The speaker has a high-conviction short thesis, believing the company's lead drug 'does not work' due to a flawed scientific hypothesis, a failed precedent drug, and weak data.